Honokiol and magnolol, as pharmacological biphenolic compounds of Magnolia officinalis, have been reported to have antioxidant and anti-inflammatory properties. Sterol regulatory element binding protein-1 c (SREBP-1 c) plays an important role in the development and processing of steatosis in the liver. In the present study, we investigated the effects of a combination of honokiol and magnolol on SREBP-1 c-dependent lipogenesis in hepatocytes as well as in mice with fatty liver due to consumption of high-fat diet (HFD). Liver X receptor α (LXRα) agonists induced activation of SREBP-1 c and expression of lipogenic genes, which were blocked by co-treatment of honokiol and magnolol (HM). Moreover, a combination of HM potently increased mRNA of fatty acid oxidation genes. HM induced AMP-activated protein kinase (AMPK), an inhibitory kinase of the LXRα-SREBP-1 c pathway. The role of AMPK activation induced by HM was confirmed using an inhibitor of AMPK, Compound C, which reversed the ability of HM to both inhibit SREBP-1 c induction as well as induce genes for fatty acid oxidation. In mice, HM administration for four weeks ameliorated HFD-induced hepatic steatosis and liver dysfunction, as indicated by plasma parameters and Oil Red O staining. Taken together, our results demonstrated that a combination of HM has beneficial effects on inhibition of fatty liver and SREBP-1 c-mediated hepatic lipogenesis, and these events may be mediated by AMPK activation.
ChitturiSAbeygunasekeraSFarrellGCHolmes-WalkerJHuiJMFungCKarimRLinRSamarasingheDLiddleCWeltmanMGeorgeJ. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology2002; 35: 373–9.
2.
MarchesiniGBugianesiEForlaniGCerrelliFLenziMManiniRNataleSVanniEVillanovaNMelchiondaNRizzettoM. Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology2003; 37: 917–23.
3.
KotronenAYki-JarvinenH. Fatty liver: a novel component of the metabolic syndrome. Arterioscler Thromb Vasc Biol2008; 28: 27–38.
4.
MatteoniCAYounossiZMGramlichTBoparaiNLiuYCMcCulloughAJ. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology1999; 116: 1413–9.
5.
Neuschwander-TetriBACaldwellSH. Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology2003; 37: 1202–19.
6.
RichardJLingvayI. Hepatic steatosis and Type 2 diabetes: current and future treatment considerations. Expert Rev Cardiovasc Ther2011; 9: 321–8.
7.
WillyPJUmesonoKOngESEvansRMHeymanRAMangelsdorfDJ. LXR, a nuclear receptor that defines a distinct retinoid response pathway. Genes Dev1995; 9: 1033–45.
8.
WatanabeKWatanabeHGotoYYamaguchiMYamamotoNHaginoK. Pharmacological properties of magnolol and honokiol extracted from Magnolia officinalis: central depressant effects. Planta Med1983; 49: 103–8.
9.
HoiCPHoYPBaumLChowAH. Neuroprotective effect of honokiol and magnolol, compounds from Magnolia officinalis, on beta-amyloid-induced toxicity in PC12 cells. Phytother Res2010; 24: 1538–42.
10.
YinHQJeYTKimYCShinYKSungSLeeKJeongGSLeeBH. Magnolia officinalis reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element-binding protein-1c. J Pharmacol Sci2009; 109: 486–95.
11.
YinHQKimYCChungYSShinYKLeeBH. Honokiol reverses alcoholic fatty liver by inhibiting the maturation of sterol regulatory element binding protein-1c and the expression of its downstream lipogenesis genes. Toxicol Appl Pharmacol2009; 236: 124–30.
12.
LoYCTengCMChenCFChenCCHongCY. Magnolol and honokiol isolated from Magnolia officinalis protect rat heart mitochondria against lipid peroxidation. Biochem Pharmacol1994; 47: 549–53.
13.
SmithPKKrohnRIHermansonGTMalliaAKGartnerFHProvenzanoMDFujimotoEKGoekeNMOlsonBJKlenkDC. Measurement of protein using bicinchoninic acid. Anal Biochem1985; 150: 76–85.
14.
JungYMLeeSHLeeDSYouMJChungIKCheonWHKwonYSLeeYJKuSK. Fermented garlic protects diabetic, obese mice when fed a high-fat diet by antioxidant effects. Nutr Res2011; 31: 387–96.
15.
LeveneA. Pathological factors influencing excision of tumours in the head and neck. Part I. Clin Otolaryngol Allied Sci1981; 6: 145–51.
16.
LudbrookJ. Update: microcomputer statistics packages. A personal view. Clin Exp Pharmacol Physiol1997; 24: 294–6.
17.
18.
BennettMKLopezJMSanchezHBOsborneTF. Sterol regulation of fatty acid synthase promoter. Coordinate feedback regulation of two major lipid pathways. J Biol Chem1995; 270: 25578–83.
19.
LopezJMBennettMKSanchezHBRosenfeldJMOsborneTF. Sterol regulation of acetyl coenzyme A carboxylase: a mechanism for coordinate control of cellular lipid. Proc Natl Acad Sci U S A1996; 93: 1049–53.
20.
ShimanoHShimomuraIHammerREHerzJGoldsteinJLBrownMSHortonJD. Elevated levels of SREBP-2 and cholesterol synthesis in livers of mice homozygous for a targeted disruption of the SREBP-1 gene. J Clin Invest1997; 100: 2115–24.
21.
SchultzJRTuHLukARepaJJMedinaJCLiLSchwendnerSWangSThoolenMMangelsdorfDJLustigKDShanB. Role of LXRs in control of lipogenesis. Genes Dev2000; 14: 2831–8.
22.
HardieDG. Minireview: the AMP-activated protein kinase cascade: the key sensor of cellular energy status. Endocrinology2003; 144: 5179–83.
23.
ImaiKInukaiKIkegamiYAwataTKatayamaS. LKB1, an upstream AMPK kinase, regulates glucose and lipid metabolism in cultured liver and muscle cells. Biochem Biophys Res Commun2006; 351: 595–601.
24.
MukaiMOzasaKHayashiKKawaiK. Various S-GOT/S-GPT ratios in nonviral liver disorders and related physical conditions and life-style. Dig Dis Sci2002; 47: 549–55.
25.
NevesRHAlencarACAguilaMBMandarim-de-LacerdaCAMachado-SilvaJRGomesDC. Hepatic stereology of Schistosomiasis mansoni infected-mice fed a high-fat diet. Mem Inst Oswaldo Cruz2006; 101(Suppl 1): 253–60.
26.
De BruyneRMFitzpatrickEDhawanA. Fatty liver disease in children: eat now pay later. Hepatol Int2010; 4: 375–85.
27.
YangSEHsiehMTTsaiTHHsuSL. Effector mechanism of magnolol-induced apoptosis in human lung squamous carcinoma CH27 cells. Br J Pharmacol2003; 138: 193–201.
28.
ShigemuraKArbiserJLSunSYZayzafoonMJohnstonePAFujisawaMGotohAWekslerBZhauHEChungLW. Honokiol, a natural plant product, inhibits the bone metastatic growth of human prostate cancer cells. Cancer2007; 109: 1279–89.
29.
ChenCRTanRQuWMWuZWangYUradeYHuangZL. Magnolol, a major bioactive constituent of the bark of Magnolia officinalis, exerts antiepileptic effects via the GABA/benzodiazepine receptor complex in mice. Br J Pharmacol2011; 164: 1534–46.
30.
ChaoLKLiaoPCHoCLWangEIChuangCCChiuHWHungLBHuaKF. Anti-inflammatory bioactivities of honokiol through inhibition of protein kinase C, mitogen-activated protein kinase, and the NF-kappaB pathway to reduce LPS-induced TNFalpha and NO expression. J Agric Food Chem2010; 58: 3472–8.
31.
MunroeMEBusingaTRKlineJNBishopGA. Anti-inflammatory effects of the neurotransmitter agonist Honokiol in a mouse model of allergic asthma. J Immunol2010; 185: 5586–97.
32.
ChenYHLinFYLiuPLHuangYTChiuJHChangYCManKMHongCYHoYYLaiMT. Antioxidative and hepatoprotective effects of magnolol on acetaminophen-induced liver damage in rats. Arch Pharm Res2009; 32: 221–8.
33.
HoKYTsaiCCChenCPHuangJSLinCC. Antimicrobial activity of honokiol and magnolol isolated from Magnolia officinalis. Phytother Res2001; 15: 139–41.
34.
CaoAHVoLTKingRG. Honokiol protects against carbon tetrachloride induced liver damage in the rat. Phytother Res2005; 19: 932–7.
35.
ChiangCKSheuMLLinYWWuCTYangCCChenMWHungKYWuKDLiuSH. Honokiol ameliorates renal fibrosis by inhibiting extracellular matrix and pro-inflammatory factors in vivo and in vitro. Br J Pharmacol2011; 163: 586–97.
36.
AhmedMHByrneCD. Modulation of sterol regulatory element binding proteins (SREBPs) as potential treatments for non-alcoholic fatty liver disease (NAFLD). Drug Discov Today2007; 12: 740–7.
37.
FerrePFoufelleF. Hepatic steatosis: a role for de novo lipogenesis and the transcription factor SREBP-1c. Diabetes Obes Metab2010; 12(Suppl 2): 83–92.
38.
PeetDJTurleySDMaWJanowskiBALobaccaroJMHammerREMangelsdorfDJ. Cholesterol and bile acid metabolism are impaired in mice lacking the nuclear oxysterol receptor LXR alpha. Cell1998; 93: 693–704.
39.
HwahngSHKiSHBaeEJKimHEKimSG. Role of adenosine monophosphate-activated protein kinase-p70 ribosomal S6 kinase-1 pathway in repression of liver X receptor-alpha-dependent lipogenic gene induction and hepatic steatosis by a novel class of dithiolethiones. Hepatology2009; 49: 1913–25.
40.
ParkKGMinAKKohEHKimHSKimMOParkHSKimYDYoonTSJangBKHwangJSKimJBChoiHSParkJYLeeIKLeeKU. Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways. Hepatology2008; 48: 1477–86.
41.
ZhangBBZhouGLiC. AMPK: an emerging drug target for diabetes and the metabolic syndrome. Cell Metab2009; 9: 407–16.
42.
DayCPJamesOF. Steatohepatitis: a tale of two “hits"?Gastroenterology1998; 114: 842–5.
43.
BonnefontJPDjouadiFPrip-BuusCGobinSMunnichABastinJ. Carnitine palmitoyltransferases 1 and 2: biochemical, molecular and medical aspects. Mol Aspects Med2004; 25: 495–520.
44.
Orellana-GavaldaJMHerreroLMalandrinoMIPanedaASol Rodriguez-PenaMPetryHAsinsGVan DeventerSHegardtFGSerraD. Molecular therapy for obesity and diabetes based on a long-term increase in hepatic fatty-acid oxidation. Hepatology2011; 53: 821–32.
FraulobJCOgg-DiamantinoRFernandes-SantosCAguilaMBMandarim-de-LacerdaCA. A mouse model of metabolic syndrome: insulin resistance, fatty liver and non-alcoholic fatty pancreas disease (NAFPD) in C57BL/6 mice fed a high fat diet. J Clin Biochem Nutr2010; 46: 212–23.
47.
FriedmanJMHalaasJL. Leptin and the regulation of body weight in mammals. Nature1998; 395: 763–70.
48.
RudermanNBCarlingDPrentkiMCacicedoJM. AMPK, insulin resistance, and the metabolic syndrome. J Clin Invest2013; 123: 2764–72.
49.
ChoiSSChaBYLeeYSYonezawaTTeruyaTNagaiKWooJT. Honokiol and magnolol stimulate glucose uptake by activating PI3K-dependent Akt in L6 myotubes. Biofactors2012; 38: 372–7.
50.
ClariaJGonzalez-PerizALopez-VicarioCRiusBTitosE. New insights into the role of macrophages in adipose tissue inflammation and fatty liver disease: modulation by endogenous omega-3 fatty acid-derived lipid mediators. Front Immunol2011; 2: 49–49.
